Cipla Ltd — Q3 FY25
Cipla reported Q3 FY25 revenue of INR 7,073 crore (+8% YoY) and EBITDA margin of 28% (+184bps YoY), driven by strong India (10% growth), South Africa (21% ZAR), and EMEU (20% US...
bullish
high
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
75%Questions answered1Evaded / deflected12Questions auditedMixedNumbers vs filing
Partial answer
High priority
US revenue trajectory, Advair/Lanreotide/Revlimid trends, and key product launch delays.
Asked by Damyanti Kerai, HSBC
Management gave qualitative trends but avoided quantifying revenue trajectory or specific launch dates.
no specific revenue numbersno timeline for Advair
Read the exchange
Question
My first question is around the US revenue trajectory. So we understand the slowdown this quarter, but if you can give us some details with regard to Advair, Lanreotide, and Revlimid, how that ended sequentially. And also, it seems like there is some delay in your key product launches in the US. How should we think about the next few quarters in terms of the US revenue trajectory?
Umang Vohra, CEO
Revlimid is sequentially more or less the same. There is no increase in Revlimid quarter on quarter. On the rest of the assets, Advair is still not launched, and we're signaling set to launch from the U.S. facility. On Abraxane, we are saying we have a definite launch at least by the end of this next year and a few months after approval.
Evasive
Medium priority
Impact of US tariffs on pharma and Cipla's strategy.
Asked by Kunal Dhamesha, Macquarie
Management declined to provide any specific view or strategy, citing lack of policy clarity.
no specific scenariodeferred to policy clarity
Read the exchange
Question
Can you provide your view on the recent comments from the U.S. President on tariff on the pharmaceutical product, and what is your base case scenario here, and what could be your strategy in the worst-case scenario?
Umang Vohra, CEO
I think we can't comment specifically because I think we have to let the policy framework of the new administration set in... we're just waiting for more color from the documented activity. But I think we're well de-risked to be able to offset some of this, as and when it comes up.
Partial answer
High priority
FY26 segment-wise growth outlook, especially US, and price erosion trends.
Asked by Kunal Dhamesha, Macquarie
Management gave qualitative pipeline details but no quantitative growth expectations or price erosion figures.
no segment-wise growth numbersno specific price erosion percentage
Read the exchange
Question
Could you provide more color on probably the segment-wise growth expectation, primarily US? I know you have indicated that Advair and Abraxane seems to be more H2 FY26 product. So beyond these couple of names, do we have other products which could help us grow? And second part to that question is, how is the price erosion in the US market evolving in the quarter three and in January?
Umang Vohra, CEO
I don't think we've seen anything abnormal on the price trajectory within the U.S. so far. ... Certainly, we have a pipeline asset, and notable in that is two or three star respiratory assets that hopefully can come in 18 to 24 months and have been filed, and we also have other peptide assets, etc., within that mix.
Answered
Medium priority
Albuterol market share potential and pricing environment.
Asked by Damyanti Kerai, HSBC
Management directly answered that market share is stabilizing and pricing erosion is marginal.
Read the exchange
Question
So in the last two quarters, you have gained significant market share. Now, you are at 21% market share as per your presentation. So do you see further room to gain market share? And also, if you can comment on the pricing environment in the Albuterol market.
Ashish Adukia, CFO
Pricing, other than marginal erosion, it's stable, and in terms of our market share, I think we are slightly more recently ahead of 21%, but that's where we see it stabilizing.
Answered
High priority
Lanreotide supply recovery trajectory and timeline.
Asked by Damyanti Kerai, HSBC
Management provided specific supply recovery percentage and timeline for full capacity.
Read the exchange
Question
You mentioned the supply issues are abating, and then maybe towards the end of March quarter, you'll be back to normalcy. But just want to understand, how should we assume the trajectory ahead, whether it will happen in phases, or you are expecting, say, a quarter down, you'll be back to the level where you have dropped?
Ashish Adukia, CFO
The endeavor is to come back to the level that we had earlier. ... We believe that from a supply perspective, we are probably about 50%-60% there. ... Our expectation right now is that the full capacity of the partner probably starts getting delivered pretty much from the end of March.
Answered
High priority
Abraxane launch timeline and reasons for delay.
Asked by Neha Manpuria, Bank of America
Management gave a clear launch window and explained the dependency on approval timing.
Read the exchange
Question
Did I hear correctly that Abraxane launch is at the back end of second half fiscal 26? And the reason for delay, given that Goa has cleared, is there anything in the application, the ANDA, that is required?
Umang Vohra, CEO
It will be your second half FY26. That's more likely outcome. ... we still have to get approval for it, and I think, obviously, we are waiting for that approval. ... it could be nine months from now. It could be six months from now. ... But we definitely expect to launch the product by quarter four of FY26.
Answered
High priority
Update on 505(b)(2) and peptide asset launches.
Asked by Neha Manpuria, Bank of America
Management provided specific counts and timelines for upcoming launches.
Read the exchange
Question
Last year, we had also mentioned a couple of 505(b)(2) assets and a few peptide assets that we expect to launch this year. Other than the Lanreotide generic launch, we haven't really seen any other large launches coming through. Can you give us an update on when do we see the 505(b)(2) assets and the rest of the peptide assets coming through for us?
Umang Vohra, CEO
We are looking at close to so we've launched about two this year, right? We have one, which we still need to launch, and we are hoping to launch it perhaps near the remainder of this year. And then we have two planned in terms of peptides in FY26. ... looking at approximately three over the next 15 months.
Partial answer
Medium priority
Reasons for strong gross margins and sustainability.
Asked by Ankush Mahajan, Axis Securities
Management explained drivers but did not quantify gross margin sustainability or provide a specific trend.
no specific gross margin numberdeferred to annual guidance
Read the exchange
Question
Very strong gross margins this time that has led to the expansion in the EBITDA also margin, so what are the reasons behind it, and how do we see the gross margins trend in upcoming quarters?
Umang Vohra, CEO
It's a combination of the mix that we have in the business. This is always the best quarter for us because of the respiratory uptake. ... quarter four is seasonally low. So overall, for the year, if you look at it, we should land at higher than the guidance that we've given of 25.5.
Answered
High priority
Lanreotide supply recovery to 100% and capacity expansion potential.
Asked by Anubhav Agarwal, UBS
Management gave specific current supply level, timeline to 100%, and potential capacity increase percentage.
Read the exchange
Question
Let's say we index our production or supply to 100 before the problem started. Once you come back in, let's say, April, would you be back to 100? ... what point of time would you, let's say, 100 will become 120 or 150 for you guys?
Umang Vohra, CEO
Right now we are at roughly close to 40%-50% of their overall index of 100, right? And we expect that by the end of March, we will be back to the 100. ... it could be 20, 25 higher. And at the same time, we are also examining other options beyond just this partner for overall capacity.
Partial answer
High priority
Potential scale-up of US respiratory portfolio to $400M by FY28.
Asked by Anubhav Agarwal, UBS
Management confirmed potential for step-function growth but avoided giving a specific dollar target.
no specific revenue targetqualitative only
Read the exchange
Question
On the respiratory portfolio today, in the US, ballpark, we are about $150-$200 million. ... FY28, for example, what kind of ramp-up could we see? This $200 million can become $400 million, let's say double from here?
Umang Vohra, CEO
Today we are slightly more than that number because we've got to Albuterol, we've got Budesonide... if your question is whether this will double, triple, it's going to be moving up step functions. It's not going to be moving marginal increases with each asset being approved.
Answered
High priority
Root cause of repeated US FDA issues and long-term fixes.
Asked by Chirag Dagli, DSP Mutual Fund
Management explained the three-pronged approach to quality improvement without evasion.
Read the exchange
Question
We've kept on seeing these crop up every once in a while. ... what is it that you're trying to do to make sure that these issues we fix these longer term? ... how are you thinking about the reasons why we've frequently gotten into these issues? And what are we doing longer term to make sure that these don't repeat?
Umang Vohra, CEO
Structurally, how we are solving this is. Its quality is a function of practice, equipment, and talent. And we have worked on all three of them. ... we have worked on all three aspects, and we will continue to work on this.
Answered
Medium priority
India business profitability improvement and sustainability.
Asked by Nitin Agarwal, DAM Capital
Management explained drivers of profitability improvement and gave a relative margin comparison.
Read the exchange
Question
On the India business, we've done reasonably well over the last few years from a revenue growth perspective. ... how has the profitability of the business sort of changed over the years? Has the profitability improved a fair bit, and where do you see what kind of opportunities do you see in this business?
Umang Vohra, CEO
Scale is a very big driver for profitability. But we've also been taking a lot of actions about optimizing our productivity. ... profitability has improved, but largely due to the fact that we've optimized our own productivity. ... It would be safe to assume that our India business profitability is slightly kind of higher than the overall company average.
Quantitative claims vs filed numbers
| Claim | Management said | Filing | Verdict |
|---|---|---|---|
| Full year EBITDA margin guidance exceeded 25.5% | 25.5% | 28% | Understated vs filing |
| Q3 EBITDA margin of 28% not sustainable | 28% | 28% | Matches filing |
Filed figures sourced from Screener.in. Claims within a small tolerance of the filing are marked “matches filing”.